Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Best Stocks For The Second Half of 2017
by Brian Bolan
A look at some stocks that are expected to show some good growth in the back half of the year.
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
Cara Therapeutics (CARA) Shows Strength: Stock Adds 12.2 % in Session
by Zacks Equity Research
Cara Therapeutics, Inc. (CARA) was a big mover last session, as the company saw its shares rise over 12% on the day
Top Ranked Momentum Stocks to Buy for June 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 27th:
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.
Exelixis Initiates Cabozantinib-Tecentriq Combination Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced that it initiated the dose-escalation stage of a phase Ib trial of cabozantinib in combination with Roche's (RHHBY) Tecentriq.
Pfizer's Kidney Cancer Drug Gets Acceptance in the U.S. & EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced encouraging news with the FDA and the European Medicines Agency (EMA) accepting the company's regulatory submission for label expansion of its cancer drug, Sutent (sunitinib).
Why Is Exelixis (EXEL) Down 20.9% Since the Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy
by Zacks Equity Research
Zacks.com featured highlights: Sonus Networks, CNH Industrial, WellCare Health Plans, Exelixis and Best Buy
Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus
by Zacks Equity Research
Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.
Play Potential Earnings Beat with These 5 Top-Ranked Stocks
by Zacks Equity Research
Bet on these top-ranked stocks that have the potential to beat the earnings estimate.
Is Intercept (ICPT) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Is Intercept (ICPT) Poised for a Beat this Earnings Season?
Apple (AAPL) to Report Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Apple, Inc. (AAPL) is set to report its second-quarter fiscal 2017 results on May 2.
What to Expect from Quotient Technology (QUOT) Q1 Earnings?
by Zacks Equity Research
Quotient Technology Inc. (QUOT) is set to report first-quarter 2017 results on May 2.
Insperity (NSP) Q1 Earnings: Is a Surprise in the Cards?
by Zacks Equity Research
Insperity, Inc. (NSP) is set to report first-quarter 2017 results on May 1.
Exelixis (EXEL) Q1 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report first-quarter 2017 results on May 1, after the market close.
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
by Zacks Equity Research
Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
M&As, Pipeline Catalysts to Drive Pharma Sector
by Arpita Dutt
The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
by Zacks Equity Research
Zacks.com featured highlights: Exelixis, U.S. Silica Holdings, Intuit and RPC
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.
4 Stocks to Buy with Superb Earnings Acceleration
by Tirthankar Chakraborty
Earnings acceleration helps spot stocks that haven't caught the attention of investors yet, which once secured will invariably lead to a rally in the share price.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.
Radius Health (RDUS) Posts Wider Loss in Q4
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a loss of $1.22 per share in the fourth quarter of 2016, compared with a loss of 77 cents per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.16.